RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

The recent past has seen impressive progress in the treatment of various malignancies using immunotherapy. One of the most promising approaches involves immune checkpoint inhibitors. However, the clinical results with these agents have demonstrated variability in the response. Pancreatic cancer, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Byunghee, Jordan, Veronica Clavijo, Sheedy, Patrick, Billig, Ann-Marie, Ross, Alana, Pantazopoulos, Pamela, Medarova, Zdravka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423142/
https://www.ncbi.nlm.nih.gov/pubmed/30886310
http://dx.doi.org/10.1038/s41598-019-41251-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423142/
https://www.ncbi.nlm.nih.gov/pubmed/30886310
http://dx.doi.org/10.1038/s41598-019-41251-9

Ejemplares similares